Cerebral venous thrombosis (CVT) is a cerebrovascular disease that most often affects young adults, especially women. CVT has a varied clinical presentation and still may be challenging to recognize. The clinical presentation is frequently subacute, but one-third of the patients present with an acute onset. The most common symptom is headache, which is present in more than 90% of the patients. About half of the CVT patients show focal neurological deficits. The spectrum of parenchymal damage due to CVT includes a wide range of manifestations, from cerebral edema to venous infarctions and intracerebral hemorrhage. However, the pathophysiological mechanisms of CVT, as well as the mechanisms underlying the effect of current treatments, are not fully understood. Additionally, there is also limited evidence on the effect of novel therapies, such as endovascular treatment, decompressive craniectomy, and NOACs.
The aim of this Research Topic is to present and discuss recent advances on cerebral venous thrombosis. We welcome Original Research Articles, Review Articles, Methods, Theory and Hypothesis, and Brief/Case Reports contributing, but not limited to advancing our understanding of:
• The pathogenic mechanisms of cerebral damage due to thrombosis
• Novel risk factors and the strength of known risk factors for cerebral venous thrombosis
• Diagnostic imaging characteristics and the added value of machine learning techniques
• Clinical course and outcome, especially with relation to the extent of venous recanalization
• Therapeutic approaches and novel developments
?Topic Editor, Dr. Jonathan Coutinho, received institutional financial support and has been involved with the RESPECT CVT trial (Boehringer Ingelheim) and EINSTEIN-JR trials (Bayer). The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Cerebral venous thrombosis (CVT) is a cerebrovascular disease that most often affects young adults, especially women. CVT has a varied clinical presentation and still may be challenging to recognize. The clinical presentation is frequently subacute, but one-third of the patients present with an acute onset. The most common symptom is headache, which is present in more than 90% of the patients. About half of the CVT patients show focal neurological deficits. The spectrum of parenchymal damage due to CVT includes a wide range of manifestations, from cerebral edema to venous infarctions and intracerebral hemorrhage. However, the pathophysiological mechanisms of CVT, as well as the mechanisms underlying the effect of current treatments, are not fully understood. Additionally, there is also limited evidence on the effect of novel therapies, such as endovascular treatment, decompressive craniectomy, and NOACs.
The aim of this Research Topic is to present and discuss recent advances on cerebral venous thrombosis. We welcome Original Research Articles, Review Articles, Methods, Theory and Hypothesis, and Brief/Case Reports contributing, but not limited to advancing our understanding of:
• The pathogenic mechanisms of cerebral damage due to thrombosis
• Novel risk factors and the strength of known risk factors for cerebral venous thrombosis
• Diagnostic imaging characteristics and the added value of machine learning techniques
• Clinical course and outcome, especially with relation to the extent of venous recanalization
• Therapeutic approaches and novel developments
?Topic Editor, Dr. Jonathan Coutinho, received institutional financial support and has been involved with the RESPECT CVT trial (Boehringer Ingelheim) and EINSTEIN-JR trials (Bayer). The other Topic Editors declare no competing interests with regard to the Research Topic subject.
